Advanced Search: Breast

For more information about any of the clinical trials listed on this site, call 314-747-7222 or 800-600-3606 toll free or email

Select Basic Search to view clinical trials grouped by category and Advanced Search to be able to further narrow search results.



EPIK-B4: A phase II, multi center, randomized, open-label, active controlled study to assess the safety and efficacy of dapagliflozin + metfromin XR versus metformin XR during treatment with alpelisib (BYL719) in combination with fulvestrant in participants with HR+, HER2-, advanced Breast Cancer with a PIK3CA mutation following progression on/after endocrine-based therapy


Endocrine Treatment Alone as Primary Treatment for Elderly Patients with Estrogen Receptor Positive Operable Breast Cancer and Low Recurrence Score


A Phase I/II Trial Evaluating the Safety and Efficacy of Eribulin in Combination with Copanlisib in Patients with Metastatic Triple Negative Breast Cancer


A Phase 1 open-label, first-in-human, multi-center study to evaluate the safety, tolerability, pharmacokinetics and anti-tumor activity of thorium-227 labeled antibody-chelator conjugate BAY 2701439, in participants with advanced HER2-expressing tumors


A Phase IB/II, 2-Stage, Open-label, Multicenter Study to Determine the Efficacy and Safety of Durvalumab (MEDI4736) in Combination with Paclitaxel and Multiple Novel Oncology Therapies and Durvalumab (MEDI4736) + Paclitaxel for First-line Metastatic Triple Negative Breast Cancer


A Phase 1, Multicenter, Open-label, Dose-Exploration and Dose-Expansion Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 650 in Subjects With Advanced Solid Tumors


A study to assess overall response rate by inducing an inflammatory phenotype in Metastatic BReast cAnCEr with the Oncolytic Reovirus PeLareorEp in CombinaTion with anti-PD-L1 Avelumab and Paclitaxel BRACELET-1 Study


BR-076: A Randomized Phase II clinical trial assessing the Efficacy and Safety of MK-3475 (pembrolizumab) in combination with carboplatin and gemcitabine in patients with metastatic triple negative breast cancer


NCI#10020 - A Phase II Open-Label, Randomized Study of PARP inhibition (Olaparib) Either Alone or in Combination with Anti-PD-L1 Therapy (Atezolizumab; MPDL3280A) in Homologous DNA Repair (HDR) Deficient, Locally Advanced or Metastatic Non-HER2-positive Breast Cancer


A Phase II Study of U3-1402 in Patients with Metastatic Breast Cancer